Exclusive Interview: Biopharma And A Biden Administration
An Interview With Greg Simon, Former Executive Director Of The Obama Administration’s Cancer Moonshot Initiative
A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”
You may also be interested in...
Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.
With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.
Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies.